BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Connolly B, Isaacs C, Cheng L, Asrani KH, Subramanian RR. SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency. J Nucleic Acids 2018;2018:8247935. [PMID: 30009048 DOI: 10.1155/2018/8247935] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Guan S, Darmstädter M, Xu C, Rosenecker J. In Vitro Investigations on Optimizing and Nebulization of IVT-mRNA Formulations for Potential Pulmonary-Based Alpha-1-Antitrypsin Deficiency Treatment. Pharmaceutics 2021;13:1281. [PMID: 34452241 DOI: 10.3390/pharmaceutics13081281] [Reference Citation Analysis]
2 Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021;:1-17. [PMID: 34394960 DOI: 10.1038/s41578-021-00358-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Steinle H, Weber J, Stoppelkamp S, Große-Berkenbusch K, Golombek S, Weber M, Canak-Ipek T, Trenz SM, Schlensak C, Avci-Adali M. Delivery of synthetic mRNAs for tissue regeneration. Adv Drug Deliv Rev 2021;179:114007. [PMID: 34710530 DOI: 10.1016/j.addr.2021.114007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Riley RS, Kashyap MV, Billingsley MM, White B, Alameh MG, Bose SK, Zoltick PW, Li H, Zhang R, Cheng AY, Weissman D, Peranteau WH, Mitchell MJ. Ionizable lipid nanoparticles for in utero mRNA delivery. Sci Adv 2021;7:eaba1028. [PMID: 33523869 DOI: 10.1126/sciadv.aba1028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
5 Qiu Y, Man RCH, Liao Q, Kung KLK, Chow MYT, Lam JKW. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Control Release 2019;314:102-15. [PMID: 31629037 DOI: 10.1016/j.jconrel.2019.10.026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
6 Crossley D, Stockley R, Sapey E. Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease? Drugs Aging 2019;36:823-40. [PMID: 31179525 DOI: 10.1007/s40266-019-00684-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Artzy-Schnirman A, Arber Raviv S, Doppelt Flikshtain O, Shklover J, Korin N, Gross A, Mizrahi B, Schroeder A, Sznitman J. Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics. Adv Drug Deliv Rev 2021;:113901. [PMID: 34331989 DOI: 10.1016/j.addr.2021.113901] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Sahu I, Haque AKMA, Weidensee B, Weinmann P, Kormann MSD. Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases. Mol Ther 2019;27:803-23. [PMID: 30905577 DOI: 10.1016/j.ymthe.2019.02.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
9 Hauser S, Poenisch M, Schelling Y, Höflinger P, Schuster S, Teegler A, Betten R, Gustafsson JÅ, Hübener-Schmid J, Schlake T, Chevessier-Tünnesen F, Horscroft N, Björkhem I, Schöls L. mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5. Mol Ther Methods Clin Dev 2019;15:359-70. [PMID: 31828178 DOI: 10.1016/j.omtm.2019.10.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
10 Swingle KL, Billingsley MM, Bose SK, White B, Palanki R, Dave A, Patel SK, Gong N, Hamilton AG, Alameh MG, Weissman D, Peranteau WH, Mitchell MJ. Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery. J Control Release 2021:S0168-3659(21)00584-8. [PMID: 34742747 DOI: 10.1016/j.jconrel.2021.10.031] [Reference Citation Analysis]
11 Damase TR, Sukhovershin R, Boada C, Taraballi F, Pettigrew RI, Cooke JP. The Limitless Future of RNA Therapeutics. Front Bioeng Biotechnol 2021;9:628137. [PMID: 33816449 DOI: 10.3389/fbioe.2021.628137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
12 Vlatkovic I. Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety. Biomedicines 2021;9:530. [PMID: 34068715 DOI: 10.3390/biomedicines9050530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 DeRosa F, Smith L, Shen Y, Huang Y, Pan J, Xie H, Yahalom B, Heartlein MW. Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy. Mol Ther 2019;27:878-89. [PMID: 30879951 DOI: 10.1016/j.ymthe.2019.03.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
14 Elkhalifa D, Rayan M, Negmeldin AT, Elhissi A, Khalil A. Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases. Biomed Pharmacother 2022;145:112385. [PMID: 34915673 DOI: 10.1016/j.biopha.2021.112385] [Reference Citation Analysis]
15 Sultana N, Hadas Y, Sharkar MTK, Kaur K, Magadum A, Kurian AA, Hossain N, Alburquerque B, Ahmed S, Chepurko E, Zangi L. Optimization of 5' Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury. Mol Ther Methods Clin Dev 2020;17:622-33. [PMID: 32300609 DOI: 10.1016/j.omtm.2020.03.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Trepotec Z, Lichtenegger E, Plank C, Aneja MK, Rudolph C. Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases. Mol Ther 2019;27:794-802. [PMID: 30655211 DOI: 10.1016/j.ymthe.2018.12.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
17 Zhao W, Hou X, Vick OG, Dong Y. RNA delivery biomaterials for the treatment of genetic and rare diseases. Biomaterials 2019;217:119291. [PMID: 31255978 DOI: 10.1016/j.biomaterials.2019.119291] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
18 Chanda PK, Sukhovershin R, Cooke JP. mRNA-Enhanced Cell Therapy and Cardiovascular Regeneration. Cells 2021;10:187. [PMID: 33477787 DOI: 10.3390/cells10010187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]